📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...